X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs BIOCON LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS BIOCON LTD NOVARTIS/
BIOCON LTD
 
P/E (TTM) x 361.2 82.9 435.8% View Chart
P/BV x 17.8 7.8 228.0% View Chart
Dividend Yield % 1.6 0.2 1,020.9%  

Financials

 NOVARTIS   BIOCON LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-16
BIOCON LTD
Mar-17
NOVARTIS/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs9821,162 84.5%   
Low Rs556483 115.3%   
Sales per share (Unadj.) Rs252.9194.6 130.0%  
Earnings per share (Unadj.) Rs62.134.4 180.6%  
Cash flow per share (Unadj.) Rs63.348.3 131.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.30.1 1,069.0%  
Book value per share (Unadj.) Rs363.6241.9 150.3%  
Shares outstanding (eoy) m31.96200.00 16.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.2 72.0%   
Avg P/E ratio x12.423.9 51.8%  
P/CF ratio (eoy) x12.217.0 71.3%  
Price / Book Value ratio x2.13.4 62.2%  
Dividend payout %16.12.9 553.6%   
Avg Mkt Cap Rs m24,580164,440 14.9%   
No. of employees `0000.89.2 8.1%   
Total wages/salary Rs m1,8017,470 24.1%   
Avg. sales/employee Rs Th10,748.94,213.9 255.1%   
Avg. wages/employee Rs Th2,395.2809.0 296.1%   
Avg. net profit/employee Rs Th2,641.1745.2 354.4%   
INCOME DATA
Net Sales Rs m8,08338,911 20.8%  
Other income Rs m8291,571 52.8%   
Total revenues Rs m8,91340,482 22.0%   
Gross profit Rs m2349,795 2.4%  
Depreciation Rs m372,772 1.3%   
Interest Rs m2260 0.7%   
Profit before tax Rs m1,0258,334 12.3%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7521,616 46.5%   
Profit after tax Rs m1,9866,881 28.9%  
Gross profit margin %2.925.2 11.5%  
Effective tax rate %73.419.4 378.3%   
Net profit margin %24.617.7 138.9%  
BALANCE SHEET DATA
Current assets Rs m12,67840,477 31.3%   
Current liabilities Rs m2,43316,783 14.5%   
Net working cap to sales %126.760.9 208.1%  
Current ratio x5.22.4 216.1%  
Inventory Days Days3360 54.9%  
Debtors Days Days2283 27.1%  
Net fixed assets Rs m6945,073 0.2%   
Share capital Rs m1601,000 16.0%   
"Free" reserves Rs m11,46047,377 24.2%   
Net worth Rs m11,62148,377 24.0%   
Long term debt Rs m021,082 0.0%   
Total assets Rs m14,40093,942 15.3%  
Interest coverage x570.533.1 1,726.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.4 135.5%   
Return on assets %13.87.6 181.6%  
Return on equity %17.114.2 120.2%  
Return on capital %23.612.6 187.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m18612,988 1.4%   
Fx outflow Rs m1,8217,899 23.1%   
Net fx Rs m-1,6355,089 -32.1%   
CASH FLOW
From Operations Rs m2,5316,400 39.5%  
From Investments Rs m-8,270-4,985 165.9%  
From Financial Activity Rs m-386-1,775 21.7%  
Net Cashflow Rs m-6,125-473 1,294.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 2.0 8.4 23.8%  
FIIs % 1.6 10.7 15.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.9 108.0%  
Shareholders   41,647 109,995 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 23, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS